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Abstract
Introduction: Peripartum cardiomyopathy (PPCM) patients refractory to medical therapy and intra-aortic balloon
pump (IABP) counterpulsation or in whom weaning from these therapies is impossible, are candidates for a left
ventricular assist device (LVAD) as a bridge to recovery or transplant. Continuous-flow LVADs are smaller, have a
better long-term durability and are associated with better outcomes. Extra corporeal membrane oxygenation
(ECMO) can be used as a temporary support in patients with refractory cardiogenic shock. The aim of this study
was to evaluate the efficacy and safety of mechanical support in acute and critically ill PPCM patients.
Methods: This was a retrospective search of the patient database of the Ghent University hospital (2000 to 2010).
Results: Six PPCM-patients were treated with mechanical support. Three patients presented in the postpartum
period and three patients at the end of pregnancy. All were treated with IABP, the duration of IABP support
ranged from 1 to 13 days. An ECMO was inserted in one patient who presented with cardiogenic shock, multiple
organ dysfunction syndrome and a stillborn baby. Two patients showed partial recovery and could be weaned off
the IABP. Four patients were implanted with a continuous-flow LVAD (HeartMate II
®, Thoratec Inc.), including the
ECMO-patient. Three LVAD patients were successfully transplanted 78, 126 and 360 days after LVAD implant; one
patient is still on the transplant waiting list. We observed one peripheral thrombotic complication due to IABP and
five early bleeding complications in three LVAD patients. One patient died suddenly two years after transplantation.
Conclusions: In PPCM with refractory heart failure IABP was safe and efficient as a bridge to recovery or as a
bridge to LVAD. ECMO provided temporary support as a bridge to LVAD, while the newer continuous-flow LVADs
offered a safe bridge to transplant.
Introduction
Peripartum cardiomyopathy (PPCM) is a rare disease
that affects women in the last month of their pregnancy
or in the early puerpium (up to five months after deliv-
ery); it is characterized by left ventricular systolic dys-
function and symptoms of heart failure without any
identifiable cause of heart failure. The incidence varies
from 1:15,000 to 1:1,300 deliveries in some African
countries and 1:299 in Haiti and is thought to be lower
in Europe [1,2]. The historically bad prognosis with
mortality rates ranging from 4 to 80% has improved
because of advances in heart failure treatment [3].
Although already described in the 19
th century the
condition was only defined as Peripartum Cardiomyopa-
thy in 1971 by Demakis et al., who also proposed diag-
nostic criteria that later were confirmed during the
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2000 [4]. Several etiologies have been proposed compris-
ing myocarditis, auto-immune mechanisms and preg-
nancy associated hormonal changes [5-7]. Recent data
support the hypothesis that PPCM may develop as a
result of complex interactions of pregnancy-associated
factors against a susceptible genetic background [8,9].
The oxidative stress-cathepsin D-16 kDa prolactin
hypothesis has been raised as a possible common path-
way on which different etiologies that induce PPCM
may merge. While newer therapies such as bromocrip-
tine appear promising and will be tested in larger trials
one must also concentrate on an optimal treatment
strategy for the acute and critically ill PPCM patients,
allowing to increase survival in this young patient popu-
lation [10].
Heart transplantation is an accepted treatment option
for patients with refractory heart failure due to PPCM,
although a higher incidence of rejection has been
reported in parous women, particularly in the first six
months after transplantation [11,12]. Moreover, heart
transplantation is limited by a lack of suitable donors.
On the other hand there is a reasonable possibility of
partial or complete recovery of left ventricular function,
during the first year. The main predictors for recovery
are an initial left ventricular end-diastolic dimension
<56 mm and an ejection fraction >45% at two months
[3]. As a consequence there is a need for appropriate
temporary short- and long-term artificial support for the
acute and critically ill patients. There are only a few
reports on mechanical support devices as a bridge to
recovery or transplantation in this setting. Data on the
use of intra aortic balloon pump (IABP) and extra cor-
poreal membrane oxygenation (ECMO) in PPCM are
scarce [13-16]. There are a few reports on the use of
pulsatile assist devices in this setting, most of them as a
bridge to transplant and in a minority of cases as bridge
to recovery [17-24].
Continuous-flow LVADs are a newer type of assist
devices that have advantages over the older pulsatile
devices: they are smaller, have a better long-term dur-
ability and their use is associated with improved survival
and functional capacity [25,26]. There are no published
series on the use of a continuous-flow device in patients
with PPCM.
Materials and methods
A retrospective 10-year study (2000 to 2010) was con-
ducted of our patient database (Department of Cardiol-
ogy, Ghent University Hospital, Belgium) for patients
with a need for mechanical support in the acute phase
of PPCM. Mechanical support was defined as IABP,
ECMO or LVAD. We received local Ethical Committee
approval and informed consent from the patients or
their relatives.
Diagnosis of PPCM was based upon development of
symptoms of heart failure due to systolic dysfunction in
the last month of pregnancy or within five months after
delivery without any identifiable cause of heart failure or
recognizable heart disease prior to the last month of
pregnancy. Patients with hypertensive heart failure in
the peripartum period were not included. Demographic,
clinical, hemodynamic and echocardiographic data as
well as data on serology were evaluated. Data on endo-
myocardial biopsies and coronary angiography were
reviewed. The outcomes of the different treatment stra-
tegies as well as their complications were evaluated.
Results
Over a 10-year period six PPCM patients were treated
with mechanical support for acute heart failure at our
center (Table 1). All six patients were treated with an
IABP and one patient was treated with ECMO. Four
patients were implanted with a continuous-flow LVAD
(HeartMate II
®, Thoratec Inc., Pleasanton, California,
USA), three of them were transplanted and one patient
is still on the transplant waiting list. The mean age at
presentation was 34.7 years, the mean body surface area
(BSA) was 1,76 m
2. Five patients were Caucasian, one
was native African. All patients but one were multipar-
ous with the number of pregnancies ranging from two
to four. Serology was examined for Coxsackie virus B1-
5, Mycoplasma pneumoniae, toxoplasmosis, hepatitis B
and C, HIV, Ebstein-Barr and adeno- and entero-virus
in all patients. Active infection with Mycoplasma pneu-
moniae was found in two patients but active myocarditis
was excluded by means of endomyocardial biopsy.
Endomyocardial biopsies in two other patients, taken at
the time of placement of the LVAD, were also negative
for myocarditis.
Presentation in the postpartum period
Patient 1 was a 34-year-old patient (G4A0P4) who pre-
sented with acute pulmonary edema 16 days after deliv-
ery of a healthy son. She was initially treated with
intravenous diuretics and vasodilators, but her condition
only stabilized after insertion of an IABP. After initiation
of conventional heart failure therapy with ACE-inhibi-
tors, diuretics and low dose beta-blockers the patient
was easily weaned off the IABP and discharged home
four weeks after admission. She is still in follow-up and
doing well under treatment with beta-blocking agents.
Patient 2 was a 35-year-old South African woman
(G2A0P2) who developed progressive dyspnea from the
fifth month postpartum. She came to the Emergency
Room a few months later with a clinical picture of
severe decompensated heart failure with lactate acidosis
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Page 2 of 7and liver failure. After initiation of inotropic therapy and
IABP insertion her condition stabilized with complete
resolution of the lactate acidosis and liver function.
Despite initiation of proper heart failure therapy, wean-
i n go f ft h eI A B Pw a sn o tp o s s i b l ea n dt h ei m p l a n t a t i o n
of a LVAD was decided. The implantation was compli-
cated by a rupture and large hematoma of the descend-
ing aorta for which an endoprosthesis was inserted.
During the early postoperative phase 2 revisions were
necessary because of pericardial tamponade. Long-term
antibiotic therapy was initiated because of infection of
the pocket. After a long postoperative period the patient
could be mobilized and discharged home 67 days after
placement of the LVAD. No recovery in left ventricular
function was noted during follow-up. A total of 126
days after implantation of the LVAD she was success-
fully transplanted and did well. Unfortunately she died
suddenly two years later, she developed electromechani-
cal dissociation during hospitalization for heart failure
due to mild rejection, prolonged resuscitation was
unsuccessful. An autopsy was not performed.
Patient 3, a 36-year-old mother of four children, pre-
sented very late in the postpartum period (18 months
postpartum), she developed progressive symptoms of
heart failure during the first months after her last deliv-
ery. She presented with cachexia and decompensated
heart failure. The left ventricular end-diastolic diameter
w a s7 9m ma tp r e s e n t a t i o n .After minor decongestion
with diuretics, low dose dopamine was started and an
IABP was inserted because of refractory hypotension
and low output failure. Five days later an LVAD was
implanted electively because of lack of left ventricular
recovery and the impossibility to wean the patient off
the IABP and dopamine. The postoperative course was
complicated by a spontaneous rectus hematoma at the
11
th postoperative day (supratherapeutic prothrombin
time) and a thrombotic occlusion of the right common
femoral artery. The arterial occlusion was a consequence
of the IABP and a thrombectomy was performed at Day
35 post LVAD with good clinical resolution afterwards.
During ambulatory follow-up, left ventricular end dia-
stolic diameter decreased from 79 to 72 mm without
recovery of left ventricular function.
Presentation late in pregnancy
Two patients presented with acute decompensated heart
failure and were in New York Heart Association class
III. An IABP was inserted in both patients prior to cae-
sarian section.
Patient 4, a 37-year-old nullipara could be weaned off
the IABP four days later and is still under treatment
with conventional heart failure therapy and is doing
well.
Patient 5, a 38-year-old woman (G2A0P1) could be
weaned off the IABP after six days but remained sympto-
matic the following weeks with severe hypotension neces-
sitating a continuous dopamine infusion. She was treated
with bromocriptine but remained inotrope-dependent.
Table 1 Patient characteristics
Patient 1 2 3 4 5 6
Year 2001 2008 2010 2007 2008 2009
Age (y) 34 35 36 37 38 28
BSA (m
2) 1.90 1.88 1.58 1.83 1.60 1.79
Race CA C C C C
Obstetrical Hx G4A0P4 G2A0P2 G4A0P4 G1A0P0 G2A0P1 G3A1P1
Symptom onset 3wPP 5mPP 5mPP 38wPr 35wPr 38wPr
Diagnosis 3w PP 10mPP 18mPP 38wPr 36wPr 38wPr
Clinical picture APE ADHF ADHF ADHF ADHF CS
LVEDD (mm) 55 62 79 53 61 68
Serology Negative Mycoplasma IgM Negative Negative Negative Myocplasma IgM
Coronary angio Normal - Normal - Normal -
Biopsy - Negative Negative - Negative Negative
IABP (d) 71 3 5 4 6 1
ECMO (d) -- - - - 7
LVAD (d) - 126 Since 26/04/2010 - 360 78
Complications - Perop. rupture aorta
Tamponade 2x
Pocket Infection
Rectus hematoma
Occlusion AFC
- - Bleeding anast. aorta
Outcome Recovery Tx, SD 535 days postTx Alive, on Tx list Recovery Tx Tx
A, African; APE, acute pulmonary edema; ADHF, acute decompensated heart failure; AFC, Arteria Femoralis Communis; anast, anastomosis; BSA, body surface area;
C, Caucasian; CS, cardiogenic shock; d, days; Hx, history; LVEDD, left ventricular end diastolic diameter at presentation; Perop, peroperative; PP, postpartum; Pr,
pregnancy; SD, sudden death; Tx, cardiac transplantation; Y, year.
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the IABP. There were no complications. Follow-up echo-
cardiography showed some recovery of left ventricular
function but the right ventricular function remained
moderate; a trial to remove the LVAD was not
attempted. She was successfully transplanted almost one
year after LVAD placement and is still doing well.
The sixth patient, a 28-year-old G3A1P1 developed
rapidly progressive dyspnea at the end of pregnancy.
Heart failure was initially not recognized and delivery
was induced with prostaglandins. Afterward she rapidly
progressed to cardiogenic shock. She was referred to
our center. During transport a continuous infusion with
adrenaline was initiated because of severe shock. Upon
arrival the patient was immediately intubated, mean-
while an IABP was percutaneously inserted. A stillborn
baby was delivered by caesarean section. The patient
remained in shock with severe lactate acidosis and mul-
tiple organ dysfunction syndrome despite treatment
with dobutamine, levosimendan and high doses of nora-
drenaline. Her condition worsened rapidly, she was not
stable enough for implantation of a LVAD. An ECMO
was percutaneously inserted at the bedside without
complications. The system comprised a Medos Hilite
7000 LT oxygenator (Medos Medizintechnik AG, Stol-
berg, Germany) and a Sorin revolution centrifugal pump
(Sorin Group, Arvado, Colorado, USA) (18 Fr arterial
line: femoral approach, 18 Fr venous line: jugular
approach). The following days we noted respiratory and
metabolic improvement. Because of the absence of left
ventricular recovery a LVAD was implanted after seven
days of ECMO. There was a revision at Day 1 because
of bleeding at the anastomosis of the aortic cannula.
During the postoperative course she was treated for ven-
tilator associated pneumonia with complete recovery.
Sildenafil treatment for moderate right ventricular func-
tion and pulmonary hypertension was initiated at the
fourth day post-LVAD implantation until transplant.
She was discharged home 37 days after initial admission
and was successfully transplanted 78 days after LVAD
implant and is doing well up till now.
Discussion
We describe six well-documented cases of severe PPCM
that presented with acute heart failure requiring
mechanical support. The diagnosis was based upon
development of symptoms of heart failure in the last
month of pregnancy or during the first five months after
delivery without arguments for pre-existing structural
heart disease. In each patient an extensive work-up was
performed to exclude other causes of heart failure. Two
patients had arguments for active Mycoplasma pneumo-
niae infection, but myocarditis was excluded by means
of endomyocardial biopsies.
We describe short- and/or long-term mechanical sup-
port when intensive medical therapy fails to stabilize a
PPCM patient with severe heart failure. Mechanical
short-term support can be provided percutaneous with
IABP or ECMO. An IABP can easily be placed at the
bedside and has little side effects in this young patient
population. There are no randomized data on the use of
IABP in non-ischemic refractory heart failure and Eur-
opean guidelines recommend insertion of an IABP when
inotropes fail to restore the blood pressure and signs of
hypoperfusion persist [27]. In our series the use of IABP
up to 13 days was complicated by one thrombotic
occlusion of the common right femoral artery, which
was corrected uneventfully after thrombectomy. All
patients treated with IABP were anticoagulated with
unfractionated heparin (UFH) aiming at an activated
partial thromboplastin time (aPTT) of 65 to 85 seconds.
Weaning from the IABP is usually attempted over one
to three days by gradually decreasing the 1:1 support to
a 1:2 and a 1:3 support. If a 1:3 support is well tolerated
for at least four hours, the IABP is removed. When
weaning off the IABP is not possible, the IABP is
removed at the time of implantation of the ECMO or
the LVAD.
There is a current trend to use short-term support
with ECMO in refractory cardiogenic shock but data
from large randomized trials are lacking. ECMO is con-
sidered an emergency rescue therapy for patients with
refractory cardiogenic shock; their condition is so
unstable that they are not eligible for immediate LVAD
implantation. The ECMO can be inserted at the bedside;
it is relatively cheap (as compared to the implantable
LVAD) and gives the treating physicians some time to
wait for recovery or a more stable condition. However,
close monitoring of the coagulation parameters is
needed and it is, therefore, labour-intensive. Patients on
ECMO are treated with UFH in order to obtain an acti-
vated clotting time (ACT) of 170 to 200 seconds.
Antithrombin III (ATIII) levels are analyzed daily, ATIII
concentrate is given if the ATIII activity drops below
70%. A visco-elastic coagulation measurement is
checked twice daily or whenever bleeding occurs.
Patients on arterio-venous ECMO are ventilated with
conventional settings, with a FiO2 to achieve an accepta-
ble PaO2 ( a tl e a s t6 0m m H G ) .I n o t r o p i cs u p p o r ti s
reduced and stopped but milrinone is often continued
for its dilator properties and positive effects on micro-
circulation. Fluid management is aimed at preserving
renal function and ensuring a stable circulation. As
ECMO flow depends on right atrial filling, this is moni-
tored by means of echocardiography. During a weaning
attempt each partial decrease in ECMO flow should be
c o m p e n s a t e db ya ni n c r e a s ei ns t r o k ev o l u m ew i t h o u t
excessive increase in inotropic support. There are three
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as a safe bridge to recovery [14-16]. In our series
ECMO was used in one patient because of refractory
cardiogenic shock and multiple organ dysfunction syn-
drome one-day post caesarean section. ECMO allowed
hemodynamic and metabolic stabilization. In contrast to
the above mentioned case reports we saw no recovery of
left ventricular function and in our patient ECMO
served as a bridge to LVAD.
LVADs offer a more long-term support. In a recent
position statement Sliwa et al. promote the use of a
mechanical assist device in PPCM in case of refractory
heart failure despite optimal medical therapy [28]. The
continuous-flow HeartMate II was introduced in 2004
and has shown improvement in survival, reduction in
adverse events and improved functional capacity [25].
This axial flow pump draws the blood on a continuous
basis from the left ventricle via an apical drainage can-
nula and propels it back into the aorta by a rotary pump
in a nonphasic flow pattern. Its smaller size makes it
suitable for patients with a low BSA, which is frequently
the case in this young female population. After implanta-
tion of the LVAD NO-ventilation is routinely applied in
our center to support the right ventricle, inotropic sup-
port is gradually decreased and replaced by oral heart
failure therapy. Echocardiography is used to assess left
ventricular filling, a neutral interventricular septum posi-
tion indicates adequate left ventricular filling. Bleeding
complications in the immediate postoperative phase still
pose a problem but recent data on the HeartMate II
device support a less aggressive anticoagulation protocol
[18,22]. More recently late bleeding complications up to
44.3% have been observed in continuous-flow LVAD
patients, possibly due to an acquired von Willebrand
Syndrome [29]. In our center the antithrombotic regimen
is started as soon as drain output reaches levels of 50 ml/
h or less. It comprises Aspirin 100 mg and Enoxaparin 40
mg once daily (20 mg in case of GFR < 30 ml/minte, 60
mg in case of body weight >90 kg). Acenocoumarol (tar-
get INR 1.5 to 2) is started as soon as a more stable
hemodynamic condition is reached and in the absence of
bleeding. Bleeding complications were observed in three
patients during the early postoperative phase, with need
for revision in two patients. We observed no late bleeding
complications. Infection of the pocket with the need for
long-term antibiotic treatment occurred in one patient.
There were no thrombotic complications related to the
LVAD, despite the fact that PPCM is a pro-thrombotic
condition. Right heart failure, defined as the postopera-
tive need for temporary right ventricular mechanical or
inotropic support for more than 14 days following
implantation, was not noted although one patient was
treated until transplantation with a low dose Sildenafil.
Neurological complications did not occur in this small
series. Sufficient recovery of left ventricular function to
allow LVAD explantation is rare but has been described
in PPCM patients treated with pulsatile devices, we
found no data on explantation of continuous-flow devices
in PPCM patients. In our series we saw a decrease in left
ventricular end-diastolic diameter and some improve-
ment in left ventricular function, but the right ventricular
function remained moderate. In our opinion the decrease
in left ventricular end diastolic diameter (LVEDD) and
improvement in left ventricular function can be attribu-
ted to the unloading of the left ventricle.
These six patients presented over a wide time range
between 2001 and 2010 with a trend towards an increas-
ing incidence over the last three years at our center, this
stresses the need for a national and international regis-
try for this pathology. One could argue that the therapy
has become more invasive over the years; the first two
patients being managed with IABP alone. However, the
more invasive therapy (ECMO, LVAD) in the patients
who presented later is attributable to the more severe
Figure 1 Algorithm for the treatment of acute and critically ill
PPCM. PPCM, peripartum cardiomyopathy; HF, Heart Failure; (*) =
Avoid ACE-inhibitors, angiotensin II receptor blockers and
aldosterone antagonists during pregnancy; cf-LVAD, continuous-flow
left ventricular device; ECMO, extracorporeal membrane
oxygenation; IABP, intra aortic balloon pump; MODS, multiple organ
dysfunction syndrome.
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patients off IABP and/or intravenous inotropes.
Despite the fact that bromocriptine appears promising
as a novel disease-specific treatment, we initiated it
briefly in one patient (patient 5) and stopped it after
implantation of the LVAD. Currently it is not clear
whether the results of the proof of concept study by
Sliwa et al., where bromocriptine was added to standard
heart failure therapy (ACE-inhibitors, aldactone, beta-
blockers and diuretics), canb ee x t r a p o l a t e dt ot h i s
patient population dependent of IV inotropes and/or
mechanical support. We hope that future trials will
address this question.
Conclusions
In acute and critically ill PPCM patient’s, mechanical
support with IABP, even prior to delivery, is safe and
feasible and serves as a bridge to partial recovery or as a
bridge to LVAD. ECMO can serve as a bridge to LVAD,
in case of refractory cardiogenic shock despite IABP and
full inotropic support. The newer continuous-flow assist
devices are a safe bridge to transplant for PPCM
patients who cannot be weaned off intravenous inotro-
pic support or mechanical support with IABP or
ECMO. The role of bromocriptine treatment in these
patients needs to be explored in future trials. Based on
the literature and our experi e n c ew ep r o p o s ea na l g o -
rithm for the treatment of acute and critically PPCM
(Figure 1).
Key messages
￿ Acute and critically ill PPCM patients, refractory to
medical therapy, should be treated with mechanical
support.
￿ IABP support is feasible and safe in the pre- and
postpartum period as a bridge to recovery or as a
bridge to assist device.
￿ In patients with refractory cardiogenic shock and
Multiple Organ Dysfunction Syndrome despite
I A B P ,E C M Os h o u l db ec o n s i d e r e da sat e m p o r a r y
‘emergency rescue’ support (bridge to recovery or
bridge to LVAD).
￿ Continuous-flow left ventricular assist devices are
safe as a bridge to transplant in this young patient
population.
￿ Bromocriptine, a novel disease-specific treatment,
can be considered in these patients.
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